Mereo BioPharma Group plc received a second notice from Nasdaq indicating it has not yet regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market. The company was granted an additional 180-day compliance period, extending until February 16, 2027, to restore its stock price above the threshold. If Mereo fails to meet this requirement by the end of the second compliance period, its securities will be subject to delisting, though it retains the right to appeal such a determination to a Nasdaq Hearings Panel. The filing notes that these notices have no immediate effect on the current listing status and management intends to monitor the closing bid price while considering available options to regain compliance. Mereo BioPharma Group plc operates in the biotechnology industry, focusing on the development of therapies for rare diseases.

Mereo BioPharma Group plc reported a net loss of $7.0 million for the second quarter ended June 30, 2026, compared to $14.6 million in the prior year period, driven by reduced R&D and G&A expenses. The company entered into an option and license agreement with Sentynl Therapeutics for alvelestat, potentially yielding up to $475 million in payments upon exercise. Mereo updated its cash runway guidance, stating that $30.1 million in cash as of June 30, 2026, is expected to fund operations into late-2027. Additionally, the company and partner Ultragenyx are engaging with regulators regarding setrusumab for osteogenesis imperfecta, with further updates expected by year-end 2026. Mereo BioPharma Group plc operates in the biopharmaceutical industry, developing innovative therapeutics for rare diseases.

On August 11, 2026, Mereo BioPharma Group plc entered into an Option and License Agreement with Sentynl Therapeutics, Inc. for U.S. commercial rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Under the deal, Mereo retains global development leadership and rest-of-world commercial rights while granting Sentynl an option to acquire U.S. licensing rights. Upon exercise of the option, Mereo is eligible to receive $40 million in upfront and R&D payments, up to $435 million in potential regulatory and commercial milestones, and double-digit tiered royalties on U.S. net sales. The companies will collaborate during a short option period to refine the Phase 3 study design, with development potentially initiating in early 2027. Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for rare diseases.